Pall Corporation will equip WuXi Biologics’ continuous bioprocess laboratory in Shanghai, China, which the latter said would expand process scale and reduce manufacturing costs.
Size can be a restricting factor when introducing single-use technologies into a pre-existing facility according to BMS, which hopes to integrate disposable equipment at a US-based site.
Sartorius Stedim Biotech (SSB) has cut its full year guidance, citing the negative impact of hurricane Maria, customer destocking and ongoing issues with a cell culture media supplier.
By Cutting the cost of vaccine manufacture, Univercells
High-density single-use bioreactors, small facilities and continuous manufacturing will cut the cost of manufacturing polio vaccines down to $0.15 per dose, says Univercells.
Faster and more flexible biomanufacturing models are necessary to reduce the cost of biologics, says Just Biotherapeutics which is building a deployable modular facility in China.
AbbVie has opened a mammalian cell culture-based drug manufacturing facility equipped with both stainless and single-use equipment, as part of a $320m investment in Singapore.
Repligen’s customer GE Healthcare opted to make its latest Protein A ligand in-house, but CEO Tony Hunt remains confident in his firm’s long-term partnerships and diversified bioprocessing offering.
The Biophorum Operations Group (BPOG) has begun working on 11 technology development projects after publishing its first roadmap, but the bioprocessing industry’s visions are forever evolving, says Sanofi-Genzyme.
The contract development and manufacturing organisation (CDMO) has selected Pall Life Sciences as its single-use equipment partner at its sites in Florida and Massachusetts.
GE Healthcare has launched a Protein A resin it says can improve monoclonal antibody purification capacity by up to 40% compared to its current offering.
Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.
Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
Filtration drove a record quarter for Repligen which says the addition of Spectrum Pharmaceuticals will further grow its bioprocessing portfolio and geographical presence.
Modular facilities and single-use systems are fast becoming a standard part of the bioproduction infrastructure as industry looks to mitigate future capacity constraints.
Pall Corporation has developed a control system for its single-use benchtop bioreactor and says it will continue to invest in-house for process control technologies.
Novartis has scaled up manufacturing of wet age-related macular degeneration (AMD) monoclonal antibody RTH258 ahead of a potential regulatory submission next year.
Supply chain issues stemming from an FDA warning letter at a facility run by its partner Lonza have dampened Sartorius Stedim Biotech’s first half 2017 results.
Lonza Group AG has predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022, citing recent acquisition Capsugel and its new Visp-based Ibex manufacturing service as drivers.
ABEC says its latest offering has twice the working volume of the 2,000L bioreactor systems generally deemed to be the upper limit in single-use bioprocessing.
Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.
Lonza will install four 2,000L single-use bioreactors at its Singapore facility to cater for growing demand for small to mid-volume biologics production.
Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.
Its new Singapore single-use plant is a fraction of the size of a conventional commercial facility but next-generation biomanufacturing at Amgen points to even smaller, more integrated sites.
Dr Reddy’s will expand its biosimilar manufacturing capacity in Hyderabad by 4,000L using GE Healthcare’s FlexFactory platform based on single-use technologies.
Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.
Stelis Biopharma has partnered with Germany’s Merck on a bioprocessing services centre in Bangalore and says single-use systems could kickstart India’s biomanufacturing sector.
Integrating single-use, automation and continuous processing equipment will be the future for bioproduction says Thermo Fisher acquisition Finesse Solution.
A WuXi Biologics facility tipped to be the world’s largest single-use mammalian cell culture site will be equipped with disposable systems from Thermo Fisher.
A second single-use production line could offer commercial-scale capacity for bispecific antibodies but Glenmark says it would need to scale-up further to support more traditional biologics.
Avid Bioservices will add multiple MilliporeSigma 2,000L bioreactors at its Californian single-use production plant in an effort to its increase annual revenue to over $100m.
Pall Corporation, GE Healthcare and LEWA Process Technologies showed off their latest downstream offerings to Biopharma-Reporter in Amsterdam last week.
Mab-Venture Biopharma has entered a collaboration to establish an antibody development and production plant in China incorporating Thermo Fisher’s single-use bioreactors and SmartFactory automated technology.
